Today: 23 January 2026
Subscribe
Browse Category

Pharmaceuticals News 16 December 2025 - 18 December 2025

Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

December 18, 2025 — Eli Lilly and Company (NYSE: LLY) is back in the spotlight after the drugmaker released new Phase 3 results for its experimental oral obesity medicine orforglipron, a development investors have been watching closely as the weight-loss market pushes beyond injections and into pills. At the same time, a report said Lilly is preparing material price cuts…
18 December 2025
····
Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is back in the market’s spotlight on December 18, 2025, after a sharp move higher driven by fresh Wall Street optimism and a growing pile of real-world “proof points” for the company’s AI-driven drug discovery thesis. The setup is classic biotech: a clinical readout starts the spark, an analyst upgrade adds oxygen, and the stock…
18 December 2025
····
Eli Lilly Stock (LLY) After Hours Dec. 17, 2025: Latest Price, Today’s Headlines, and What to Watch Before Thursday’s Open

Eli Lilly Stock (LLY) After Hours Dec. 17, 2025: Latest Price, Today’s Headlines, and What to Watch Before Thursday’s Open

Dec. 17, 2025 (After the Close, U.S. Markets) — Eli Lilly and Company (NYSE: LLY) finished Wednesday lower and then held steady in extended trading, as investors balanced a risk-off day for equities with fresh headlines on U.S. drug-pricing negotiations, ongoing “rotation” trades favoring healthcare, and new collaboration news tied to next-generation obesity therapeutics. As of 4:31 p.m. ET, LLY…
17 December 2025
····
Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

CAs of Wednesday, December 17, 2025, Johnson & Johnson (NYSE: JNJ) is back in focus for investors looking for a “defensive” large-cap healthcare stock—while also weighing two forces that can move JNJ shares quickly: drug pipeline catalysts and talc litigation headlines. JNJ shares are trading around $210 today, after a volatile stretch that included a sharp pullback on Tuesday, December…
17 December 2025
····
GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) announced today that the FDA approved Exdensur (depemokimab‑ulaa) for severe eosinophilic asthma in patients 12+. Here’s what it means for GSK’s respiratory pipeline, competition, and shareholders on 17.12.2025. GSK plc (LSE/NYSE: GSK) is in the spotlight on Wednesday, 17 December 2025, after the company confirmed US FDA approval for Exdensur (depemokimab‑ulaa)—a new twice‑yearly biologic for severe asthma—while…
17 December 2025
··
Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics Inc. (NASDAQ: GPCR) is having a classic biotech moment on Tuesday, December 16, 2025: big catalyst, big financing, and now big volatility. Shares were down about 6% in Tuesday trading, recently around $60.73, after swinging between roughly $58.95 and $65.69 intraday. The pullback comes just days after the company reported positive topline Phase 2b results for its oral…
16 December 2025
···
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is seeing a sharp pullback in Tuesday trading (Dec. 16, 2025), with shares recently changing hands around $62—down roughly 9% from the prior close—after hitting an intraday low near $59.76. That drop may look dramatic in isolation, but it’s landing on top of an unusually eventful stretch for the RNA interference (RNAi) biotech: Arrowhead just…
16 December 2025
···
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Inc. (NYSE: PFE) shares fell sharply in U.S. trading on Tuesday, December 16, 2025, as investors weighed the drugmaker’s first look at full-year 2026 guidance, an updated 2025 revenue outlook, and fresh commentary on cost savings and capital allocation. By late morning ET, Pfizer stock was trading around $25, down roughly 5% on the day after swinging between the…
16 December 2025
····
Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

December 16, 2025 — Johnson & Johnson stock (NYSE: JNJ) is trading lower on Tuesday after pushing to fresh highs earlier this week, as investors weigh a mix of pipeline momentum, legal headlines, and an approaching earnings update that could clarify the company’s 2026 trajectory. StockAnalysis Below is what’s moving Johnson & Johnson shares right now, what Wall Street is…
16 December 2025
····
Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025

Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025

Eli Lilly and Company stock (NYSE: LLY) remains one of the market’s most closely watched healthcare names as 2025 winds down—powered by blockbuster demand for obesity and diabetes medicines, and increasingly driven by what comes next: faster, deeper weight loss therapies, an oral GLP-1 pipeline, and a manufacturing expansion designed to keep up with demand. In early trading on Tuesday,…
16 December 2025
····
Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer’s latest outlook is setting the tone for how investors may view the drugmaker’s post-pandemic transition in 2026: steady underlying growth ambitions, but a near-term financial “air pocket” as COVID-19 revenue continues to shrink and several products face patent and exclusivity headwinds. On December 16, 2025, Pfizer issued its full-year 2026 guidance, projecting revenue of $59.5 billion to $62.5 billion…
16 December 2025
···
Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025)

Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025)

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is still living inside one of the more dramatic biotech story arcs of 2025: eye-popping clinical data, followed immediately by a massive equity raise, followed by a flurry of analyst price-target resets. As of Tuesday, December 16, 2025, TERN shares were trading around $44. That price level matters because it sits right on top of…
16 December 2025
····
1 … 24 25 26 27 28 … 46

Stock Market Today

  • Sysco (SYY) Shows Undervaluation Amid Steady Share Performance and DCF Analysis
    January 22, 2026, 8:36 PM EST. Sysco (SYY) shares have delivered a steady 7.2% return over the past year, recently trading around $76.84. A Discounted Cash Flow (DCF) analysis, which estimates intrinsic value from future free cash flows discounted to present value, suggests the stock is trading at a 52.3% discount with an intrinsic value of approximately $161.19 per share. Sysco's free cash flow is projected to grow from $1.67 billion today to about $4.68 billion by 2035. The stock's price-to-earnings (P/E) ratio stands at 20.3 times, below industry and peer averages, implying room for growth. Investors are weighing Sysco's resilience as a leading foodservice distributor amid ongoing economic cycles. The current valuation signals potential undervaluation, positioning Sysco as a candidate for long-term investment consideration.
Go toTop